NeoCura Bio-Medical Technology Co., Ltd. ("NeoCura") and Beijing GenePlus Technology Co., Ltd ("Gene⁺") signed a strategic cooperation agreement at Beijing recently. In the agreement, NeoCura will leverage Gene⁺'s testing platform technology to accelerate the early clinical trial progress of mRNA tumor neoantigen vaccines. And Gene⁺ will play to its advantages in performance, application, and data security of sequencing platforms to jointly promote precision treatment of tumors and build a new ecosystem of industry chain cooperation.

NeoCura's co-founder and CEO, Wang Yi, and Gene⁺'s CEO, Yi Xin, signed the Agreement on behalf of the both companies respectively.

As a high-tech enterprise focusing on AI+RNA drug development, NeoCura has always been at the forefront of the RNA-based innovative drug development field. Based on its own R&D experience and technical advantages, NeoCura has conducted in-depth researches in multiple directions, such as mRNA tumor neoantigen vaccines, tumor microenvironment immuno-modulator, and virus vaccines. Gene⁺, as an innovative high-tech enterprise focusing on precision medicine, has created a good industry reputation in the field of pharmaceutical enterprise services, relying on its rich project experience in scientific research and academic fields, a complete process solution based on domestic sequencing platforms, and a testing system that meets the standards of clinical trials of drugs. Based on the promising and forward-looking mRNA tumor neoantigen vaccines technology, the two parties can complement each other's advantages in the clinical transformation and application process to achieve win-win results.

Wang Yi, co-founder and CEO of NeoCura, said, "We are very pleased to establish a partnership with Gene⁺. NeoCura has been actively applying cutting-edge emerging technologies in the world such as multi-omics and AI algorithms to empower RNA-based innovative drug development. While, Gene⁺ has industry-leading high-throughput gene testing technology and is expanding its application in the field of tumor treatment. We look forward to complementary advantages with Gene⁺, and to continuously enriching tumor gene big data and accelerating the clinical trial process of our mRNA tumor neoantigen vaccines with advanced AI algorithm platforms and high-throughput gene testing technology. In the future, NeoCura will work with more industry peers to provide safe and effective innovative drugs for patients and contribute to 'Healthy China'."

Yi Xin, CEO of Gene⁺, said, "We attach great importance to the testing demand in the drug development process. The company has established a testing and delivery system complying with the standards of clinical trials of drugs, which can simultaneously meet the high standards required for pre-clinical research exploration and clinical trial compliance testing, and can facilitate the standardization of clinical trials and the listing of drugs. Gene⁺ continuously pursues technological innovation and product iteration, will assist NeoCura in neoantigen prediction, validation, and process improvement by means of the advantages of multi-omics platforms, and expand higher value space in future cooperation. Subsequently, the company will continue to improve, explore faster tumor detection cycles, provide more stable, reliable and compliant testing services for NeoCura and more partners, so as to achieve mutually beneficial resources and common development of the industry."

About NeoCura

NeoCura is a high-tech enterprise that relies on AI technology to create an RNA technology platform and conduct R&D of innovative drugs. The company has built multi-omics big data acquisition platforms and multiple bioomics databases. It uses AI and bioinformatics technology to conduct in-depth drug target mining and fully automated drug design for innovative RNA technology platform upgrades and drug research. 

NeoCura has a top research team with a global vision, consisting of experts from different fields, such as AI bioinformatics, tumor immunology, new vaccine development, drug delivery, and nucleic acid carriers. Its research pipelines cover multiple directions including tumor neoantigen vaccines, microenvironment immuno-modulator, and virus vaccines, etc.It has established leading R&D centers and production centers in Beijing, Shenzhen, and Guangzhou to support pipelines development, platform upgrades, and clinical demand.

About Gene⁺

Founded in 2015, Gene⁺ is a leading innovative high-tech enterprise in precision medicine in China. By adheres to the strategy of domestic independence, Gene⁺ provides gene testing products and services in the medical, scientific, and health fields based on its testing, manufacturing, and data platforms, to achieve a development path from technological breakthroughs, academic leadership, product innovation to market leadership.

In the field of pharmaceutical enterprise services, Gene⁺ provides testing products and services covering the entire chain from drug development to listing, involving preclinical target discovery, central laboratory testing and patient recruitment, companion diagnostic development (CDx) and commercialization, and post-market promotion. It has accumulated rich project experience and technical qualifications, cooperated with more than 60 well-known domestic and foreign pharmaceutical enterprises, participated in more than 200 clinical trial projects, and achieved multiple high-quality results transformation.